Abstract: A method for the determination of glycated protein in a sample characterised in that it comprises treating the sample with a protease and treating the protease-treated sample with a ketoamine oxidase, a product of this reaction being measured is disclosed.

Abstract: A method of diagnosing complicated urolithiasis consists in testing for and finding the presence of albumen in a urine sample. A portion of said sample is dried and a crystallographic study is performed. On finding a marginal amorphous area, accommodating a central crystalline area, pyelonephritis is diagnosed. On discovering a full crystalline area (i.e. with no marginal amorphous area), calculous pyelonephritis is diagnosed.The method of prognostication involves testing for and finding the absence of albumen in a urine sample. A portion of the urine sample is mixed with a 8-12% protein solution, the mixture is then dried and a crystallographic study is conducted. With a full non-transparent crystallization of the sample (i.e. without the marginal amorphous area), urolithiasis is prognosticated.

Abstract: A composition, test device and method of determining the presence or concentration of proteins, such as albumin, in a liquid test sample, such as urine. The test device includes a test pad with a carrier matrix incorporating a indicator reagent composition capable of interacting with proteins to produce a detectable response. The indicator reagent composition includes an indicator dye that is capable of interacting with albumin and undergoing a detectable color transition; a buffer; a hydrophobic polymeric compound having the general structural formula: ##STR1## wherein A is ##STR2## and PO is an oxypropylene unit, EO is an oxyethylene unit, y is a number in the range of 0 to about 20, z is a number in the range of 0 to about 20, the sum y+z is a number in the range of about 2 to about 20, and R.sub.2 and R.sub.3 are selected, independently, from the group consisting of hydrogen, an alkyl group, an aralkyl group, and an aryl group;R.sub.

Abstract: A method for measurement of fructosamines in an aqueous liquid characterized by including the steps of:(a) bringing an aqueous liquid sample into contact with one or more active oxygen producing substances;(b) bringing the product of said step (a) into contact with a reagent producing a detectable change in the presence of hydrogen peroxide derived from the active oxygen, and(c) detecting an occurrence of the detectable change of said step (b).

Abstract: A method and kit for the isolation and quantitation of glycated hemoglobin and other glycated proteins, specifically albumin, from a single sample of whole blood. Glycated hemoglobin is calculated from an eluate resulting from the contact of the whole blood hemolysate with a boronated resin. Glycated albumin and other plasma proteins are calculated using immunoturbidimetry, resulting from reaction between a buffered antibody solution and the albumin or other protein in the previous eluate.

Abstract: A kit for staining proteins and nucleic acids wherein the stain is a suspension of colloidal metal particles and the proteins and nucleic acids are visualized as a colored signal localized at the binding site of the colloidal metal particles to the proteins or nucleic acids or quantitatively determined at this site following art-known spectrophotometric procedures.

Abstract: A method of manufacturing a test device for determining the presence and concentration of proteins, such as albumin or Bence Jones proteins, in a test sample. The test device includes a carrier matrix incorporating a reactant system capable of interacting with proteins to produce a visually or instrumentally detectable and/or measurable response. The carrier matrix of the device can include commonly used bibulous matrices, such as filter paper, or a nonbibulous protein-permeable strip, membrane or layer of a polymerized urethane-containing composition. In addition, a reactant system, including a dual indicator reagent system, such as bromophenol blue, methyl orange and, if necessary, a suitable buffer, is incorporated into the carrier matrix to provide improved color resolution and increased sensitivity to proteins, thereby affording a more accurate and trustworthy protein assay of test samples, such as urine.

Abstract: The present invention provides a test kit and a process thereof for the determination of an analyte in a pasty sample, especially in faeces, containing a sample application region which has a sample layer with a sample field for the application of a sample. An analysis device with reagents is provided which reacts with the analyte and includes a component producing a detection signal. The sample layer includes a material which is capillary-active so that a liquid is transported therein by capillary action.

Abstract: Monoclonal antibodies specific for the glycosylated lysine residue at position 525 in glycoalbumin and a method for producing such antibodies. The monoclonal antibodies are useful as reagents in immunoassays for the specific determination of glycoalbumin in human blood samples which is indicative of the severity of the diabetic condition. The monoclonal antibodies are secreted by hybridomas obtained by fusing a myeloma cell with a lymphocyte that has been taken from an animal, usually a mouse, immunized with a peptide immunogen and which produces antibody to the lysine 525 residue in glycoalbumin. The synthetic peptide immunogen comprises a peptide residue which includes an .epsilon.-amino glucosylated lysine and an adjacent amino acid sequence in which at least one of the amino acid units is in a position corresponding to the peptide sequence of human albumin adjacent to lysine 525, the glycosylated peptide residue being linked to an immunogenic carrier.

Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are preferentially reactive with glycated albumin and insignificantly reactive with other proteins, as well methods of using these monoclonal antibodies to detect glycated albumin.

Abstract: A method and composition for the assay for albumin at an essentially neutral to an alkaline pH. The method utilizes indicator dyes that, when sufficiently buffered in a pH range of approximately 6 to approximately 8, allows the detection of albumin in urine or serum. The indicator dyes utilized in the method of the present invention have the general formula: ##STR1## wherein R.sub.1 and R.sub.2 are substituted aromatic heterocyclic or carbocyclic moieties having one or more electron-withdrawing functionalities present on the aromatic ring; R.sub.3 is a substituted aromatic heterocyclic or carbocyclic moiety having one or more electron-withdrawing functionalities present on the aromatic ring, or R.sub.3 is a non-aromatic electron-withdrawing moiety; R.sub.4 is a substituted quasi-aromatic quinone-like heterocyclic or carbocyclic moiety having one or more electron-withdrawing functionalities present on the quasi-aromatic quinone-like ring; and R.sub.

Abstract: An optical method for quantitative determination of human serum albumin (HSA) in biological liquids such as urine is based on the observation that the absorption and fluorescence of certain anionic cyanine dyes possessing a terminal cyano group and having the general formula ##STR1## are strongly affected by HSA. This approach is distinctly more sensitive than existing techniques, allowing the detection and quantization of micro-albuminuria (i.e. detection of HSA in the 1-10 mg per liter concentration range) at costs which are distinctly lower than those for existing immunological assays. It is also much more specific for HSA than existing assays based on dye binding. Because the dyes has long wave absorptions and emissions, use can be made of electro-optical components based on semiconductor technology.

Abstract: This invention teaches a process for reducing protein matrix effects in assays for serum fructosamine. Blood or blood derived samples are used, and one adds two reagents, one of which reduces interference caused by non-specific reducing substances, the other of which eliminates turbidity. Incubation follows, and then the pH of the sample is adjusted and color forming reagent is added. In one embodiment, the incubation time is only 1-15 minutes. In another embodiment, the first reagent contains peroxidase.

Abstract: There is provided a method for determination of hydroxyacetophenone derivatives such as 3,5-dichloro-4-hydroxyacetophenone in the presence of protein such as albumins or globulins with high sensitivity. The hydroxyacetophenone derivative can be measured in the neutral to acidic region, whereby the method is not affected by interferrants such as bilirubin or hemoglobin. The hydroxyacetophenone derivatives are useful as the chromogen of synthetic substrates for determining acid phosphatase activity.

Abstract: Process for the specific determination of the serum fructosamine content in blood or in samples obtained from blood by reaction with an appropriate color reagent and measurement of the color change thereby brought about, in which before the color reaction sample components with a non-specific reducing action and/or causing turbidity are removed and subsequently the color reagent is added at a pH value of from 10 to 12. The sample components are removed by treatment at approximately neutral pH value with a reagent composition comprising at least one enzymatic oxidation agent, optionally together with peroxidase and/or catalase and/or lipase, as well as with at least one SH group-blocking substance. A kit for the specific determination of the serum fructosamine content in blood or samples obtained from blood, comprises said reagent composition, a rebuffering reagent with a buffer which has an alkaline pH value and a color reagent for the detection of fructosamine.

Abstract: A detection and quantification technique for radioisotope labeled components separated in a capillary separation channel. The section of the separation channel containing the separated components is significantly cooled to substantially eliminate diffusion of the components while detection is being carried out. The section can be frozen and autoradiography technique or solid state electronic imaging technique can be utilized to obtain an image representative of the relative amounts of separated components.

Abstract: This invention provides a primary standard and/or secondary standards for assay for glycated proteins in samples such as blood. The primary standard is composed of a polymer or copolymer of an amino acid, such as lysine, serine or those listed on table 37 (pages 100-110 of the second edition of Organic Chemistry by Robert Morris and Robert Nielson-Boyd) glycated with a known amount of glucose, preferably .sup.14 C glucose or .sup.3 H glucose, and free of unbound glucose. The preferred secondary standards are composed of glycated native protein per se, or a mixture of a glycated native protein and native protein that has been standardized against a primary standard to give the actual glycated protein value. These primary standards and secondary standards may be packaged and sold as a kit that contains a primary standard and/or a secondary standard and the reagents needed to perform the glycated protein assay.

Abstract: An improved method for determining the approximate consumption rate of alcohol by a human subject includes the steps of using are blood sample from such subject to develop a subject serum panel. Such serum panel includes at least twelve constituents, preferably more. Two of the constituents are HDL and magnesium. The subject blood serum panel is then statistically compared with a reference panel providing categories of rates of alcohol consumption such as light-to-moderate, moderate-to-heavy and very heavy. The reference panel also includes HDL and magnesium as constituents. That category of alcohol consumption which best characterizes such subject is then identified, thereby diagnosing the approximate alcohol consumption rate and, therefore, the presence or absence of probable alcohol abuse. Selenium, copper and/or zinc may also be included as constituents. Reference and subject panels may also be developed to include considerations of gender and ranges of age.

Abstract: A test device and method of determining the presence and concentration of proteins, including albumin and Bence Jones proteins, in a test sample are disclosed. The test device includes a test pad comprising a new and improved carrier matrix incorporating an indicator reagent composition capable of interacting with proteins to produce a visually or instrumentally detectable and/or measurable response. The new and improved carrier matrix of the test pad comprises a fibrous, bibulous substrate, such as filter paper, homogeneously impregnated with a polymerized urethane-based compound dispersed in a liquid vehicle comprising an aprotic solvent and an alcohol. The resulting non-greening carrier matrix provides improved color resolution and increased sensitivity to proteins in dry phase test strip assays, thereby affording a more accurate and trustworthy protein assay of liquid test samples, such as urine.

Abstract: A dry multilayer analysis element which allows easy permeation of a high molecular weight component or hydrophobic component, which has, in order, at least a water permeable porous reagent layer, a water permeable light reflecting/screen layer, and a water permeable porous spreading layer on a water-impermeable transparent support, a reagent composition capable of producing an optically detectable substance in the presence of a component to be detected being incorporated in at least one of the water-permeable layers including said reagent layer, said light reflecting/screen layer being porous and comprised microcapsules having a core containing light reflective/screen grains and a shell made of a high molecular weight compound, wherein each of said reagent layer, spreading layer, and reflecting/screen layer allows permeation of a high molecular weight or hydrophobic component therethrough.

Abstract: Serum is reacted with a dinitrohalobenzene compound and the rate of halogen formation is measured. This rate is in proportion to the amount of albumin in the sample. Other proteins like the globulins, as well as free aminoacids and urea, do not interfere with this reaction.

Abstract: A test device and method of determining the presence and concentration of proteins in a test sample are disclosed. The test device includes a test pad comprising a new and improved carrier matrix incorporating an indicator reagent composition capable of interacting with proteins to produce a detectable or measurable response. The new and improved carrier matrix of the test pad comprises a film, membrane or layer of a polymerized urethane-based compound, a water insoluble inorganic compound and an insoluble organic compound. The carrier matrix provides improved color resolution and increased sensitivity to proteins in dry phase test strip assays, thereby achieving an accurate and trustworthy protein assay of a liquid test sample, such as urine, having a protein concentration as low as about 5 mg/dL. Also disclosed is a method of making the test device.

Abstract: A test device and method of determining the presence and concentration of proteins, such as albumin or Bence Jones proteins, in a test sample. The test device includes a carrier matrix incorporating a reactant system capable of interacting with proteins to produce a visually or instrumentally detectable and/or measurable response. The carrier matrix of the device can include commonly used bibulous matrices, such as filter paper, or a nonbibulous protein-permeable strip, membrane or layer of a polymerized urethane-containing composition. In addition, a reactant system, including a dual indicator reagent system, such as bromophenol blue, methyl orange and, if necessary, a suitable buffer, is incorporated into the carrier matrix to provide improved color resolution and increased sensitivity to proteins, thereby affording a more accurate and trustworthy protein assay of test samples, such as urine.

Abstract: For the determination of fructosamine in body fluids a solution containing fructosamine and albumin is used as the standard solution for calibration which standard solution is essentially free of glucose and which has a pH between 5.0 and 6.0 and contains at least 10 mmol/l buffer.

Abstract: A single color determination method of quantization of the amount of fructosamine in a sample such as serum by removing other interfering reducing agents and developing a color with a coloring agent such as tetrazolium salt.

Abstract: There is disclosed herein an automated sample preparation system for chemical assay of samples of materials. The sample preparation system includes a sample preparation chamber which includes a removable cup for taking to the location of solid or very viscous samples. The cup may be attached in sealing relationship to a cap through which extends various utilities such as a mixer/grinder to grind solid samples and mix non-homogeneous samples, a fill pipe to pump in liquid samples, an effluent pipe in the sump of the cup to allow pump of samples and solvents and a nozzle to allow liquids to be sprayed against the walls. A sample metering valve associated with the sample preparation chamber allows a known volume of sample to be isolated so that solvent may be pumped in to dilute the sample to a user defined concentration.

Abstract: Cu.sup.+ produced during the reaction of protein with alkaline Cu.sup.++ can be monitored by measuring the absorbance at 562 nm of the intense purple complex formed with the ion of bicinchoninic acid (BCA). The color produced is stable and increases in a linear fashion over a broad working range of increasing protein concentration. Since BCA is stable, it is incorporated in the reagent formulation at the start of the reaction. Thus, the method offers mechanical simplification over the method described by Lowry et al.

Abstract: Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias, such as AD. The onset and progression of dementia are diagnosed and monitored by following changes in the relative concentrations of two forms of albumin in either serum or CSF. The onset and progression of dementia are controlled and memory loss is impeded or the impairment of memory is improved by dietary supplementation or the administration of Mg.

Abstract: A bridging molecule carrying a drug, or a label such as a fluorophore, which adds across disulfide bonds of molecules, particularly proteins, and methods of manufacturing and using the bridging molecules, are disclosed. The bridging molecule is reactive with sulfhydryl groups formed by the reduction of disulfide bonds of the protein. The functional groups of the bridging molecules are typically --SH groups.

Abstract: An improved method and reagents are disclosed for determining a ligand in an assay solution containing the ligand, a reagent system and a luminescent compounds, wherein the intensity of the light emitted by the assay solution is related to the change in the transmittive properties of the assay solution produced by the interaction of the ligand to be determined and a reagent system capable of producing a change in the transmittive properties of the assay solution in the presence of the ligand.

Abstract: A method for testing skin for presence of moisturizing substances is provided which method includes the steps of applying to the skin a moisturizer formulation which includes protein, urea and/or glucose and/or other reducing sugar such as fructose all of which bind with water and form a film or coating on the skin which inhibits moisture loss from the skin, and subsequently testing the skin for the presence of protein, urea and/or glucose and/or other reducing sugar remaining on the skin which is directly correlated to the amount of moisturizer formulation remaining on the skin. When it is determined through the testing that there has been at least a predetermined loss of protein, urea and/or glucose or other reducing sugar, additional moisturizer is then applied to the skin.

Abstract: The determination of fructosamine levels in at least part of a blood sample for use in detecting diabetes in patients or deciding treatment levels is effected by controlling the temperature and pH of the sample, adding a coloring agent such as a nitro-blue tetrazolium and after a first delay in time taking a first color measurment at a predetermined wavelength and after a second delay in time taking a second color measurement at the predetermined wavelength, then comparing any resultant change between the first and second color measurements with those of standard solutions, the selected timing delays, wavelength, coloring agent and pH conditions being such that any change of color in the coloring agent between the first and second color measurements is caused predominantly by the glucose in the sample that is reacted with an amine group of protein and has undergone a molecular rearrangement to form fructosamine and not materially by any non-specific reducing substance which may be present in the sample.

Abstract: The determination of fructosamine levels in at least part of a blood sample for use in detecting diabetes in patients or deciding treatment levels is effected by controlling the temperature and pH of the sample, adding a coloring agent such as a nitro-blue tetrazolium and after a first delay in time taking a first color measurement at a predetermined wavelength and after a second delay in time taking a second color measurement at the predetermined wavelength, then comparing any resultant change between the first and second color measurements with those of standard solutions, the selected timing delays, wavelength, coloring agent and pH conditions being such that any change of color in the coloring agent between the first and second color measurements is caused predominantly by the glucose in the sample that is reacted with an amine group of protein and has undergone a molecular rearrangement to form fructosamine and not materially by any non-specific reducing substance which may be present in the sample.

Abstract: Disclosed herein is an assay for determination of albumin in a liquid sample. This assay involves the use of a dye of the structure: ##STR1## wherein n is zero or a positive integer up to 3; R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, alkyl, cycloalkyl, aryl, alkoxy, aroxy, hydroxy, carboxy, alkoxycarbonyl, amino or a nonaromatic heterocyclic group; and Z and Z.sub.1 independently represent the carbon, nitrogen, oxygen or sulfur atoms needed to complete a substituted or unsubstituted 5- to 7-membered carbocyclic or heterocyclic ring. This dye has a high affinity for albumin over a wide pH range. When the dye is bound to albumin, a shift in the dye spectral absorption occurs. Analytical elements containing this dye and an assay method are disclosed herein.

Abstract: Colored proteins having a known molecular weight of 1800 to 321200 are prepared by coupling monomers of a colored protein having a known molecular weight or by coupling a colored protein having a known molecular weight with a colorless protein having a known molecular weight. At least two proteins are selected from the so prepared colored proteins and used as a colored molecular weight marker. This colored molecular weight marker is used for determination of the molecular weight of a protein having an unknown molecular weight, and can also be used as a reference protein for purification of a protein having a known molecular weight.

Abstract: Method, kits and reagents for the simultaneous, kinetic spectrophotometric analysis of blood serum samples for multiple components. Pairs of components which may be simultaneously analyzed are: cholesterol and triglyceride; glucose and urea; uric acid and gamma glutamyl transferase; calcium and magnesium; albumins and total protein.